Pharmaceutical companies lack financial incentives to develop pediatric medications and treatments

Drug manufacturers systematically avoid investing in pediatric drug development because the market is smaller and less profitable than adult medications, leaving children without adequate treatment options for serious conditions. Healthcare systems and pediatric providers struggle to access innovative therapies for their young patients, while pharmaceutical companies face no compelling business case to overcome the higher regulatory burden and smaller addressable market of pediatric care.